UNLIMITED FREE
ACCESS TO THE WORLD'S BEST IDEAS

SUBMIT
Already a GlobalSpec user? Log in.

This is embarrasing...

An error occurred while processing the form. Please try again in a few minutes.

Customize Your GlobalSpec Experience

Select Your Free Newsletters

Industry Newsletters

Select Your Free Product Alerts

Finish!
Privacy Policy

This is embarrasing...

An error occurred while processing the form. Please try again in a few minutes.

HHS - 21 CFR PART 212

CURRENT GOOD MANUFACTURING PRACTICE FOR POSITRON EMISSION TOMOGRAPHY DRUGS

active, Most Current
Organization: HHS
Publication Date: 1 April 2016
Status: active
Page Count: 10

Document History

21 CFR PART 212
April 1, 2022
CURRENT GOOD MANUFACTURING PRACTICE FOR POSITRON EMISSION TOMOGRAPHY DRUGS
A description is not available for this item.
21 CFR PART 212
April 1, 2021
CURRENT GOOD MANUFACTURING PRACTICE FOR POSITRON EMISSION TOMOGRAPHY DRUGS
A description is not available for this item.
21 CFR PART 212
April 1, 2019
CURRENT GOOD MANUFACTURING PRACTICE FOR POSITRON EMISSION TOMOGRAPHY DRUGS
A description is not available for this item.
21 CFR PART 212
April 1, 2018
CURRENT GOOD MANUFACTURING PRACTICE FOR POSITRON EMISSION TOMOGRAPHY DRUGS
A description is not available for this item.
21 CFR PART 212
April 1, 2017
CURRENT GOOD MANUFACTURING PRACTICE FOR POSITRON EMISSION TOMOGRAPHY DRUGS
A description is not available for this item.
21 CFR PART 212
April 1, 2016
CURRENT GOOD MANUFACTURING PRACTICE FOR POSITRON EMISSION TOMOGRAPHY DRUGS
A description is not available for this item.
21 CFR PART 212
April 1, 2015
CURRENT GOOD MANUFACTURING PRACTICE FOR POSITRON EMISSION TOMOGRAPHY DRUGS
A description is not available for this item.
21 CFR PART 212
April 1, 2014
CURRENT GOOD MANUFACTURING PRACTICE FOR POSITRON EMISSION TOMOGRAPHY DRUGS
A description is not available for this item.
View Less
View All
Advertisement